Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNew: DTG/3TC Switch vs TAF Continuation for Bone Health in HIV
NCT03549689Phase 2Withdrawn
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dolutegravir + lamivudine in osteopenia (2 arms). Primary endpoint: Percent change in lumbar spine Bone Mineral Density at 96 weeks. Planned start Aug 2019; status: withdrawn.
02
Drugs
dolutegravir + lamivudine
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT03549689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549689.